Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Nervous System Diseases

Infections

Musculoskeletal Diseases

Rare Diseases

Recurrence

Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Glioblastoma

Glioma

Brain Neoplasms

Medulloblastoma

Burkitt Lymphoma

Meningioma

Spinal Cord Neoplasms

Astrocytoma

Ependymoma

Craniopharyngioma

Adamantinoma

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Choroid Plexus Neoplasms

Lymphomatoid Granulomatosis

Leukemia

Leukemia, Lymphoid

Lymphoma, Non-Hodgkin

Ameloblastoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Disease Attributes

Neoplasms, Neuroepithelial

Neoplasms, Germ Cell and Embryonal

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Hematologic Diseases

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Lymphoma, B-Cell

Neoplasms, Vascular Tissue

Meningeal Neoplasms

Precancerous Conditions

Bone Neoplasms

Bone Diseases

Cerebral Ventricle Neoplasms

Spinal Cord Diseases

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Germ Cells Tumors

Brain Tumor, Childhood

Neuroepithelioma

Childhood Brain Stem Glioma

Supratentorial Primitive Neuroectodermal Tumor

Medulloblastoma, Childhood

Cerebellar Astrocytoma, Childhood

Cerebral Astrocytoma, Childhood

Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified

B-cell Lymphoma

Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

ispinesib

laboratory biomarker analysis

pharmacological study

Richard Sills

This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose and recommended phase II dose of ispinesib in pediatric patients with refractory solid tumors or lymphoma.

II. Define and describe the toxicities of ispinesib in these patients. III. Characterize the pharmacokinetics of ispinesib in these patients.

SECONDARY OBJECTIVES:

I. Define, preliminarily, the antitumor activity of ispinesib. II. Determine the relationship between CYP3A4 gene polymorphisms and pharmacokinetics in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of ispinesib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients undergo blood and tumor sample collection periodically for pharmacokinetic and gene polymorphism correlative studies.

After completion of study therapy, patients are followed for 30 days.

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

National Cancer Institute (NCI)

Spots Global Cancer Trial Database for recurrent childhood grade iii lymphomatoid granulomatosis